full spectrum cell analysis®
eBioscience®

Anti-Human LMO2 Purified

Catalog Number: 14-9899
RUO: For Research Use Only



Immunohistochemistry of human tonsil tissue at a 1:1000 dilution of Anti-Human LMO2 Purified followed by Anti-Mouse IgG Biotin (cat. 13-4013) and avidin HRP (cat. 18-4100). Low (left) and high (right) magnifications are shown.

Product Information

Contents: Anti-Human LMO2 Purified
REF Catalog Number: 14-9899
Clone: 1A9-3B11
Concentration: 0.5 mg/ml
Host/Isotype: Mouse IgG1

Formulation: aqueous buffer, 0.09% sodium azide, may contain carrier protein/stabilizer
Temperature Limitation: Store at 2-8°C.
LOT Batch Code: Refer to Vial
Use By: Refer to Vial
Caution, contains Azide

Description

This 1A9-3B11 monoclonal antibody reacts with human LMO2, a member of the LIM-only family of zinc finger proteins. LMO2 possesses two LIM domains for homodimerization and an N-terminal transactivation domain. This 24-kDa transcription factor can be found as part of a transcriptional complex composed of TAL1, E47, GATA-1, and LDB1 proteins. LMO2 is expressed in myeloid cells, germinal center B cells, vascular endothelium, and a variety of cancers, including diffuse large B cell lymphomas (DLBCL), T cell acute lymphoblastic lymphomas, and vascular neoplasms. Expression of LMO2 in germinal center B cells has been shown to be regulated by microRNAs, specifically hsa-miR-223. Although the function of LMO2 remains unclear in germinal center B cells, this factor is involved in hematopoiesis and oncogenesis. In addition, expression of this molecule has been demonstrated to be prognostic marker for survival in DLBCL patients.

Applications Reported

This 1A9-3B11 antibody has been reported for use in immunohistochemical staining.

Applications Tested

This 1A9-3B11 antibody has been tested by immunohistochemistry on human tonsil tissue and western blot on the Raji cell line. This can be used at 0.5-10 µg/mL. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.

References

Malumbres R, Sarosiek KA, Cubedo E, Ruiz JW, Jiang X, Gascoyne RD, Tibshirani R, Lossos IS. Differentiation-stage-specific expression of microRNAs in B-lymphocytes and diffuse large B-cell lymphomas. Blood. 2008 Dec 1.

Natkunam Y, Farinha P, Hsi ED, Hans CP, Tibshirani R,et al. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J Clin Oncol. 2008 Jan 20;26(3):447-54.

Natkunam Y, Zhao S, Mason DY, Chen J, Taidi B, Jones M, Hammer AS, Hamilton Dutoit S, Lossos IS, Levy R. The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas. Blood. 2007 Feb 15;109(4):1636-42.

Wadman IA, Osada H, Grütz GG, Agulnick AD, Westphal H, Forster A, Rabbitts TH. The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1 and Ldb1/NLI proteins. EMBO J. 1997 Jun 2;16(11):3145-57.

Related Products

13-4013 Anti-Mouse IgG Biotin (Polyclonal)
14-4714 Mouse IgG1 K Isotype Control Purified
18-4100 Avidin HRP

Tel: 888.999.1371 or 858.642.2058 • Fax: 858.642.2046 • www.eBioscience.com • info@eBioscience.com